Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

SAN DIEGO, May 11, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2009.

Arena reported a net loss allocable to common stockholders in the first quarter of 2009 of $50.6 million, or $0.68 per share, compared to a net loss allocable to common stockholders in the first quarter of 2008 of $55.0 million, or $0.75 per share.

"Receiving the positive lorcaserin BLOOM results was a significant milestone for Arena, and we are focusing our financial, management and development resources on completing the lorcaserin BLOSSOM trial on schedule and submitting our New Drug Application for lorcaserin by the end of the year," stated Jack Lief, Arena's President and Chief Executive Officer. "Given the challenging economic environment, we made the difficult decision to reduce the number of employees and limit our research programs to provide additional financial flexibility for this primary objective."

"As previously announced, during the first year of the BLOOM trial, 47.5% of lorcaserin patients lost 5% or more of their body weight from baseline, compared to 20.3% in the placebo group, exceeding the efficacy benchmark in the most recent FDA draft guidance," stated William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "Patients on lorcaserin rapidly lost a medically important amount of weight in a well-tolerated manner, with about one-third losing at least 5% of their body weight in only eight weeks. Lorcaserin helped nearly half of the patients to lose at least 5% of their body weight, and nearly a quarter to lose 10% or more of their body weight. We look forward to presenting these and additional data at the upcoming American Diabetes Association meeting in June."

As expected, research and deve
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 01, 2014 Chantel Lee ’15 and Eli ... 10 40-hour weeks with Dr. Juan Rodriguez, Professor of Physics, ... a common diabetic eye disease caused by changes in the ... and Eli accomplished is quite remarkable,” said Rodriguez. “They took ... when they started, and together carried it to near completion ...
(Date:8/1/2014)... CHICAGO , Aug. 1. 2014 As ... U.S., the 2014 AACC Annual Meeting & Clinical Lab ... testing and patient care are introduced to the healthcare ... by the Expo,s 650 exhibitors will include the latest ... Advances in smartphones and biosensors have enabled ...
(Date:8/1/2014)... Research and Markets has announced ... (SNP) Genotyping and Analysis Market 2014-2018" report to ... Single Nucleotide Polymorphism (SNP) genotyping is the ... the genome of various species. SNPs are commonly present ... technology can analyze thousands of SNPs and has the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Testing ... led to a better understanding embryonic development. ... reorganize into structurally and functionally distinct tissues is ... defects. Prof. Todd McDevitt, Melissa Kinney, and ... signals interact with biochemical cues to control many ...
Breaking Biology Technology:Two Centenary College Students Tackle Diabetic Retinopathy Research 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Study Links Biomechanics and Gene Expression in Stem Cells 2
... , 3Q09 Corporate Highlights: , ... Europe Ltd. Made significant progress in commercial readiness ... Director, Marketing; and Director, Commercial Operations Appointed Bradford S. ... , Upcoming 2009 Milestones: , ...
... Nov. 6 Intarcia Therapeutics, Inc. delivered two presentations ... exenatide) program for the treatment of type 2 diabetes ... Francisco, CA: , (Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) , ... Lowers Plasma Glucose, HbA1c and Reduces Weight in a ...
... , GAITHERSBURG, Md., Nov. 5 GenVec, Inc. (Nasdaq: GNVC ... September 30, 2009. GenVec reported a net loss of $3.6 million ... compared to a net loss of $6.8 million ($0.08 per share) ... September 30, 2009, GenVec,s net loss was $14.1 million ($0.15 per ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
(Date:7/31/2014)... first-of-its-kind study of bigeye tuna movements in the northwestern ... Large Pelagics Research Center at the University of Massachusetts ... a wide geographical range with pronounced north-south movements from ... a high-use area off Cape Hatteras southwest of Bermuda ... new approach to study one of the most important ...
(Date:7/31/2014)... U.S. Census Bureau, Latinos are the largest minority group ... Approximately one-third of Latinos are obese and are ... non-Hispanic Whites. , NYU College of Nursing student ... to identify the factors that contribute to this problem ... focused on food patterns in Latina women recently published ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
Breaking Biology News(10 mins):Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... fever wax and wane over a period of several ... the incidence and range of the potentially deadly mosquito-borne ... has never been more important. , A new study ... a brief period of cross-immunity conferred by any one ...
... led by a conservationist from the Bronx Zoo-based Wildlife ... European Union project CURESS near Chad's Zakouma National Park, ... only their tusks -- a sure sign that poaching ... protected area. , Mike Fay, a WCS conservationist and ...
... genes with a single injection into a vein holds ... heart, University of Florida researchers report. , UF researchers ... with a form of muscular dystrophy that damages the ... monkeys and found genes were readily absorbed by heart ...
Cached Biology News:UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3Widespread elephant slaughter discovered in Chad 2UF scientists test improved gene therapy method for hereditary heart conditions 2UF scientists test improved gene therapy method for hereditary heart conditions 3UF scientists test improved gene therapy method for hereditary heart conditions 4
... RNAi Services offer you a full ... studies. B-Bridges advanced design parameters, effective ... ensure that you obtain quality results ... Design Service utilizes their proprietary B-Algo ...
... SNPs, Polymorphic uses proven, validated Sanger dideoxy ... analysis. We use high throughput capillary sequencing ... by sequencing in both directions. The use ... information, further confirming the location of the ...
... The Sub-Cell Model 96 and PowerPac basic power ... of nucleic acids in agarose gels. This Model ... x 10 cm UV-transparent gel tray with fluorescent ... power supply, 100-120 and 220-240 V, provides output ...
... mini ReadySub-Cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The mini ... cables and electrodes, and leveling bubble. The PowerPac ... output of 10-300 V, 4-400 mA, and 75 ...
Biology Products: